Icalziss (Calcium Chloride Dihydrate)

Calcium chloride dihydrate, the active ingredient in Icalziss, is an excipient (calcium salt) presented as a solution for injection for extracorporeal use. It is employed to restore extracellular calcium levels in patients with hypocalcemia and as a component of intravenous electrolyte solutions.

GNH USA supplies Icalziss as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide, adhering to EU GMP standards and providing validated cold‑chain logistics for injectable products. The company offers regulatory documentation, batch release certificates, and responsive technical support to ensure seamless integration into clinical pharmacy inventories.

Icalziss provides calcium ions to address disorders of calcium deficiency and is used in intravenous electrolyte management.

- Hypocalcemia: restores low serum calcium levels, helping prevent cardiac and neuromuscular complications. - Intravenous electrolyte solutions: serves as a calcium source in balanced IV fluid formulations for perioperative and critical care patients. - Calcium supplementation during renal replacement therapy: supplies calcium needed to maintain circuit stability and patient calcium balance.

Adverse reactions to Icalziss are generally related to the rapid increase of serum calcium and the properties of the injectable solution.

Common Side Effects: - Injection site pain: mild discomfort at the site of administration. - Phlebitis: inflammation of the vein used for infusion. - Hypercalcemia symptoms: transient nausea, headache, or dizziness. - Electrolyte imbalance: transient shifts in magnesium or phosphate levels.

Serious or Rare Side Effects: - Cardiac arrhythmias: potentially life‑threatening rhythm disturbances. - Tissue necrosis: severe extravasation causing local tissue damage. - Severe allergic reaction: anaphylaxis, though extremely uncommon.

When using Icalziss, clinicians should observe specific precautions to minimize risks and ensure product integrity.

- Verify serum calcium: confirm hypocalcemia and baseline calcium levels before administration. - Infuse slowly: administer via controlled infusion to avoid rapid calcium spikes. - Monitor cardiac function: continuous ECG monitoring is recommended during infusion. - Assess renal function: impaired kidneys may reduce calcium clearance. - Avoid concurrent calcium‑containing medications: prevent additive calcium load. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Calcium chloride can interact with several drugs, altering their efficacy or safety profile.

Major Interactions (Avoid): - Digoxin: increased risk of digoxin toxicity due to calcium‑mediated effects on cardiac conduction. - Calcium channel blockers: additive hypotensive effect; monitor blood pressure closely.

Moderate Interactions (Monitor Closely): - Loop diuretics (e.g., furosemide): may increase calcium excretion, requiring calcium level monitoring. - Bisphosphonates: concurrent use can cause hypocalcemia; ensure adequate calcium supplementation. - Antacids containing aluminum or magnesium: may reduce calcium absorption if given orally, though less relevant for IV use. - Magnesium sulfate: concurrent high doses can precipitate calcium‑magnesium complexes.